Cytokinetics, Incorporated
CYTK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.42 | -1.04 | 1.40 |
| FCF Yield | -1.77% | -3.35% | -2.88% | -1.20% |
| EV / EBITDA | -26.72 | -43.87 | -40.25 | -49.97 |
| Quality | ||||
| ROIC | -12.52% | -9.88% | -13.69% | -11.10% |
| Gross Margin | -38.38% | 96.58% | -6,223.05% | -453.13% |
| Cash Conversion Ratio | 0.35 | 0.95 | 0.82 | 0.44 |
| Growth | ||||
| Revenue 3-Year CAGR | 123.47% | 105.00% | -41.91% | -41.98% |
| Free Cash Flow Growth | 11.73% | 3.57% | -105.33% | 35.68% |
| Safety | ||||
| Net Debt / EBITDA | -2.93 | -7.26 | -5.27 | -5.55 |
| Interest Coverage | -6.34 | -4.60 | -6.78 | -6.15 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -657.85 | -627.84 | 102.11 | 68.95 |